Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

Health ProfessionalsPatients

RecruitingLast updated: 24 July 2026

Nectin-4: Evaluating how safe, tolerable and effective a targeted drug called E303 is in people with advanced or metastatic solid cancersA Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors

Trial purpose

Medical clipboardCancer treatment

Tumor type

Multi-Cancer Multi-Cancer

Age

People18+

Trial acronym

Nectin-4

Clinical summary

Summary

This study is testing a new experimental treatment called E303, which is designed to target a protein called nectin-4 found on some cancer cells.
 
E303 is an antibody-drug conjugate (ADC), meaning it combines an antibody that finds cancer cells with a chemotherapy-like drug that is delivered directly to those cells.
 
The trial is for adults with advanced solid cancers that have spread, cannot be removed with surgery, or have continued to grow despite standard treatment.
 
The main aim is to assess the safety of E303, determine appropriate dose levels, and look for signs that it may help control cancer.

Conditions

This trial is treating people with locally advanced, unresectable or metastatic solid cancers

Eligibility

Inclusion

  • Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.

Exclusion

  • Have spinal cord compression or clinically active central nervous system metastases
  • Have leptomeningeal disease
  • Have thromboembolic or clinically significant bleeding events
  • Have significant cardiovascular disease
  • Have an active autoimmune disease

Inclusion

  • You have had treatment, but your cancer has come back (relapsed or recurrent).
  • Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
  • Your cancer has not spread to other parts of the body, but it is not possible to perform surgery to remove it (unresectable).
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

Exclusion

  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Samsung Bioepis Co., Ltd.

Scientific Title

A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait